Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Exploratory analysis of early treatment discontinuation and clinical outcomes of patients with attention‐deficit/hyperactivity disorder

Exploratory analysis of early treatment discontinuation and clinical outcomes of patients with... ADHD, atomoxetine, China, clinical outcome, Introduction: This post-hoc analysis was to investigate the impact of treat- treatment discontinuation ment discontinuation on clinical outcomes in patients with attention- deficit/hyperactivity disorder (ADHD). Author Contributions Methods: Data are from a 12-month, observational, multinational study All authors were involved in drafting, critical that included outpatients aged 6–17 years who were diagnosed with revision, and approval of the manuscript. ADHD and treated with atomoxetine, methylphenidate, or nootropic Funding: This trial was funded by Eli Lilly and agents. Treatment effectiveness and proportions of patients who discon- Company and/or any of its subsidiaries, tinued treatment were compared between China and the other non- Indianapolis, IN, USA. Trial Registration: Observational study, Western countries/regions combined. Propensity score matching was used therefore no registration. to further estimate the association between treatment discontinuation and effectiveness. Correspondence Results: Of the 546 patients who entered the study, 337 patients had Tamas Treuer MD PhD, Neuroscience Research, complete data and were included in the analyses. Compared with the Eli Lilly and Company, H-1075 Budapest, other countries/regions, China subgroup had a higher treatment Madách Imre u. 13-14, Hungary. discontinuation rate (odds ratio = 25.80; P < 0.0001) and poorer treatment Tel: +36-1-328-5127 effectiveness: least-squares http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Asia-Pacific Psychiatry Wiley

Exploratory analysis of early treatment discontinuation and clinical outcomes of patients with attention‐deficit/hyperactivity disorder

Loading next page...
 
/lp/wiley/exploratory-analysis-of-early-treatment-discontinuation-and-clinical-Zuz5UmUM0i

References (38)

Publisher
Wiley
Copyright
© 2017 John Wiley & Sons Australia, Ltd
ISSN
1758-5864
eISSN
1758-5872
DOI
10.1111/appy.12231
pmid
26663807
Publisher site
See Article on Publisher Site

Abstract

ADHD, atomoxetine, China, clinical outcome, Introduction: This post-hoc analysis was to investigate the impact of treat- treatment discontinuation ment discontinuation on clinical outcomes in patients with attention- deficit/hyperactivity disorder (ADHD). Author Contributions Methods: Data are from a 12-month, observational, multinational study All authors were involved in drafting, critical that included outpatients aged 6–17 years who were diagnosed with revision, and approval of the manuscript. ADHD and treated with atomoxetine, methylphenidate, or nootropic Funding: This trial was funded by Eli Lilly and agents. Treatment effectiveness and proportions of patients who discon- Company and/or any of its subsidiaries, tinued treatment were compared between China and the other non- Indianapolis, IN, USA. Trial Registration: Observational study, Western countries/regions combined. Propensity score matching was used therefore no registration. to further estimate the association between treatment discontinuation and effectiveness. Correspondence Results: Of the 546 patients who entered the study, 337 patients had Tamas Treuer MD PhD, Neuroscience Research, complete data and were included in the analyses. Compared with the Eli Lilly and Company, H-1075 Budapest, other countries/regions, China subgroup had a higher treatment Madách Imre u. 13-14, Hungary. discontinuation rate (odds ratio = 25.80; P < 0.0001) and poorer treatment Tel: +36-1-328-5127 effectiveness: least-squares

Journal

Asia-Pacific PsychiatryWiley

Published: Mar 1, 2017

Keywords: ; ; ; ;

There are no references for this article.